menu
    • menu
    [{"orgOrder":0,"company":"Menarini","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Sodium Picosulfate","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Menarini","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Menarini \/ Lupin Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Menarini \/ Lupin Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals for disodium [4-[pyridin-2-yl-(4-sulfonatooxyphenyl)methyl]phenyl] sulfate

    Menu

    disodium [4-[pyridin-2-yl-(4-sulfonatooxyphenyl)methyl]phenyl] sulfate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Menarini

                            Italy arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Menarini

                            Italy arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Picosulfate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Lupin Ltd

                            Deal Size : $12.1 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lupin Inks Pact to Acquire 5 Drug Brands from Menarini for Rs 101 Crore

                            Details : The company has signed an agreement to acquire five legacy brands are Piclin, Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor) catering to gastroenterology, urology and anti-infective...

                            Brand Name : Piclin

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 22, 2023

                            Lead Product(s) : Sodium Picosulfate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Lupin Ltd

                            Deal Size : $12.1 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth